Results 251 to 260 of about 350,440 (325)

Impact of genotype–phenotype associations on prognosis in dilated cardiomyopathy

open access: yesEuropean Journal of Heart Failure, EarlyView.
Prediction of clinical outcomes in genetic dilated cardiomyopathy (DCM). LVEF, left ventricular ejection fraction. Aims Dilated cardiomyopathy (DCM) has a monogenic aetiology in up to 40% of patients. Understanding the spectrum of genotype–phenotype associations in DCM is crucial for risk stratification and personalized treatment.
Sophie L.V.M. Stroeks   +27 more
wiley   +1 more source

Deep phenotyping of heart failure with preserved ejection fraction through multi‐omics integration

open access: yesEuropean Journal of Heart Failure, EarlyView.
Deep phenotyping of of heart failure with preserved ejection fraction (HFpEF) through multi‐omics integration. AI, artificial intelligence. Aims Heart failure with preserved ejection fraction (HFpEF) has become the predominant form of heart failure and a leading cause of global cardiovascular morbidity and mortality.
Jakob Versnjak   +15 more
wiley   +1 more source

Associations between the Level of Trace Elements and Minerals and Folate in Maternal Serum and Amniotic Fluid and Congenital Abnormalities. [PDF]

open access: yesNutrients, 2019
Kocylowski R   +8 more
europepmc   +1 more source

Effects of semaglutide in obesity‐related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP‐HFpEF programme

open access: yesEuropean Journal of Heart Failure, EarlyView.
Abstract Background The prevalence of heart failure with preserved ejection fraction (HFpEF) increases with age, and older adults with HFpEF have worse physical function, quality of life, and clinical outcomes. Semaglutide demonstrated efficacy in the treatment of obesity‐related HFpEF in the STEP‐HFpEF trials.
Ambarish Pandey   +14 more
wiley   +1 more source

Zika Virus Infection during Pregnancy and Congenital Abnormalities. [PDF]

open access: yesFront Microbiol, 2017
Rather IA, Lone JB, Bajpai VK, Park YH.
europepmc   +1 more source

Severity of effect considerations regarding the use of mutation as a toxicological endpoint for risk assessment: A report from the 8th International Workshop on Genotoxicity Testing (IWGT)

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Exposure levels without appreciable human health risk may be determined by dividing a point of departure on a dose–response curve (e.g., benchmark dose) by a composite adjustment factor (AF). An “effect severity” AF (ESAF) is employed in some regulatory contexts.
Barbara L. Parsons   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy